The Oxford spinout received funding from the European Innovation Council Accelerator programme to commercialise its processor technology.
"Our team is diverse across gender, nationality, and academic background. Women make up one-third of the company, including two of the five founding members. We represent at least eight nationalities and speak more than ten languages. Nearly half of our team (48%) self-identifies as ethnicities other than White. Two-thirds of the team are focused on engineering, with deep expertise reflected in seven PhDs and 11 additional members holding Master’s degrees across the wider business."
The funding round was backed by a group of existing investors alongside a grant from the European Innovation Council.
"This is a very significant funding milestone in our mission to detect cancer early and improve survival and quality of life for patients. Having demonstrated our multi-cancer capability, we can now focus on building the pipeline of organ-specific tests, beginning with a multi-center study to gain regulatory approval for the brain cancer test. We will also expand our data on colorectal cancer, one of the leading causes of death worldwide, and continue our work on collaborative projects."
